Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept plus methotrexate vs usual treatment in moderate rheumatoid arthritis
2007-001625-10Phase 4Terminated
- Sponsor
- Wyeth
- Start
- Mar 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Wyeth. Primary endpoint: Change from randomization in modified Total Sharp Score (TSS) at 52 weeks. Started Mar 2008; status: terminated.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-001625-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001625-10.